Cardiovascular risk after breast cancer chemotherapy in a hospital-based real-word study from Northwest China
Abstract
BackgroundCardiotoxicity is a common adverse effect of chemotherapy in breast cancer, yet real-world evidence, particularly from Asian populations remains limited.MethodsUsing inpatient and outpatient hospital records from a major tertiary hospital centre in Xi’an, Northwest China, we tested three commonly prescribed chemotherapy regimens: Anthracyclines plus Cyclophosphamide (A+C; reference), Docetaxel plus Cyclophosphamide (D+C), and Docetaxel plus Carboplatin (D+Cb). Their associations with cardiovascular outcomes, including cardiovascular disease (CVD) accumulation measured by the number of distinct cardiovascular diagnoses, and incident CVD risk were evaluated. Models were adjusted for patient characteristics, targeted and endocrine treatments, and baseline CVD risk factors.ResultsWe identified 8672 breast cancer patients with at least one medication record. After a median follow-up of 3.2 years, 14% (n=1194) of patients developed at least one CVD event. Compared with A+C, neither D+C nor D+Cb was associated with incident CVD or specific cardiovascular outcomes. Within the first-year follow-up, patients receiving D+C showed a lower CVD accumulation (Beta=-0.34, p=0.041), and reduced risks of incident CVD (HR = 0.70, p=0.034) and cerebrovascular diseases (HR = 0.20, p=0.037) at nominal significance but did not survive after multiple testing correction. Additional adjustment for clinical stage and radiotherapy yielded no associations between chemotherapies and cardiovascular outcomes.ConclusionsCompared with A+C, D+C or D+Cb were not associated with cardiovascular outcomes. Patients treated with D+C potentially showed reduced risk of overall cardiovascular disease and cerebrovascular disease incidence within one year, with more evidence needed.
Related
- Sociocultural and religious influences on breast cancer patients undergoing chemotherapy at Ho Teaching Hospital, Ghana
- Correlation of Axillary Nodal with Breast Response Following Neoadjuvant Chemotherapy in Early Breast Cancer
- Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer
- Empowering women through teach-back education: A protection motivation theory approach to breast cancer prevention in Northwest Iran
- 142 DCE-MRI radiogenomics predicts immune microenvironment subtypes and neoadjuvant chemotherapy response in HR+/HER2− breast cancer
BibTeX
@article{li2026cardiovascular,
title = {{Cardiovascular risk after breast cancer chemotherapy in a hospital-based real-word study from Northwest China}},
author = {Danyang Li and Jiao Yang and Xi Chen and Lin Nan and Jin Gong and Xiao Liang and Lingxia Zeng and Jin Yang},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1997067},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1997067},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cardiovascular risk after breast cancer chemotherapy in a hospital-based real-word study from Northwest China
AU - Danyang Li
AU - Jiao Yang
AU - Xi Chen
AU - Lin Nan
AU - Jin Gong
AU - Xiao Liang
AU - Lingxia Zeng
AU - Jin Yang
PY - 2026
DA - 2026/11/05
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1997067
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1997067
AB - BackgroundCardiotoxicity is a common adverse effect of chemotherapy in breast cancer, yet real-world evidence, particularly from Asian populations remains limited.MethodsUsing inpatient and outpatient hospital records from a major tertiary hospital centre in Xi’an, Northwest China, we tested three commonly prescribed chemotherapy regimens: Anthracyclines plus Cyclophosphamide (A+C; reference), Docetaxel plus Cyclophosphamide (D+C), and Docetaxel plus Carboplatin (D+Cb). Their associations with cardiovascular outcomes, including cardiovascular disease (CVD) accumulation measured by the number of distinct cardiovascular diagnoses, and incident CVD risk were evaluated. Models were adjusted for patient characteristics, targeted and endocrine treatments, and baseline CVD risk factors.ResultsWe identified 8672 breast cancer patients with at least one medication record. After a median follow-up of 3.2 years, 14% (n=1194) of patients developed at least one CVD event. Compared with A+C, neither D+C nor D+Cb was associated with incident CVD or specific cardiovascular outcomes. Within the first-year follow-up, patients receiving D+C showed a lower CVD accumulation (Beta=-0.34, p=0.041), and reduced risks of incident CVD (HR = 0.70, p=0.034) and cerebrovascular diseases (HR = 0.20, p=0.037) at nominal significance but did not survive after multiple testing correction. Additional adjustment for clinical stage and radiotherapy yielded no associations between chemotherapies and cardiovascular outcomes.ConclusionsCompared with A+C, D+C or D+Cb were not associated with cardiovascular outcomes. Patients treated with D+C potentially showed reduced risk of overall cardiovascular disease and cerebrovascular disease incidence within one year, with more evidence needed.
SN - 2234-943X
ER -